Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M. Younossi, Victor Ankoma‐Sey, James F. Trotter et al.|The Lancet|2019Cited by 1.2k
Pathogenesis of non-alcoholic fatty liver diseaseJ. K. Dowman, Philip N. Newsome|QJM|2009Cited by 732
Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohortMatthew J. Armstrong, Philip N. Newsome, Diarmaid D. Houlihan et al.|Journal of Hepatology|2011Cited by 304
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver DiseaseHuapeng Lin, Hye Won Lee, Terry Cheuk‐Fung Yip et al.|JAMA|2024Cited by 200
A global research priority agenda to advance public health responses to fatty liver diseaseHenry E. Mark, Alina M. Allen, Juan Pablo Arab et al.|Journal of Hepatology|2023Cited by 132